SIM0610

SIM0610 is a bispecific antibody-drug conjugate (BsADC) developed by Jiangsu Simcere Pharmaceutical Co., Ltd. (through its subsidiary Simcere Zaiming) for the treatment of advanced solid tumors. It simultaneously targets two key oncogenic drivers: the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition factor (cMET). The drug consists of a humanized anti-EGFR/cMET bispecific antibody conjugated to a topoisomerase I inhibitor (TOP1i) payload via a cleavable hydrophilic linker. SIM0610 is designed to overcome resistance to EGFR-targeted therapies and exhibits potent anti-proliferative activity, including a bystander effect that allows it to suppress tumor growth even in cells with low target expression. It is currently being evaluated in a first-in-human Phase 1 clinical trial for patients with locally advanced or metastatic solid tumors, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and hepatocellular carcinoma.